http://about.me/troyewilsonTroy E. Wilson, Ph.D., J.D., is one of Kura’s co-founders and has served as our President and Chief Executive Officer and as the chairman of our Board of Directors since our inception in August 2014. Previously, Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, and its parent company Araxes Pharma LLC from July 2012 to March 2019 and as President and Chief Executive Officer of Avidity Biosciences LLC, a privately-held biopharmaceutical company, from November 2012 to February 2019. Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privately-held biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceutical Company Limited. He has also been a member of the board of directors of Puma Biotechnology, Inc., a publicly-held biopharmaceutical company, since October 2013, Executive Chairman and a member of the board of directors of Avidity Biosciences, Inc. since February 2019 and November 2012, respectively, Executive Chairman and a member of the board of directors of Wellspring Biosciences since February 2019 and July 2012, respectively, and a member of the board of managers of Araxes Pharma LLC since July 2012. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.
-
President And Chief Executive OfficerKura Oncology, Inc. Aug 2014 - PresentSan Diego, California, UsKura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. -
Executive Chairman Of The Board Of DirectorsWellspring Biosciences Nov 2012 - PresentWellspring and its parent company, Araxes Pharma, are closely held and committed to creating breakthrough medicines for the treatment of cancer and other serious diseases. The companies were founded by Yi Liu, Ph.D., Pingda Ren, Ph.D., Kevan Shokat, Ph.D. and Troy Wilson, Ph.D., J.D., based upon pioneering research into KRAS G12C inhibitors conducted by Dr. Shokat, HHMI Investigator and Professor of Molecular and Cellular Pharmacology, and colleagues at the University of California, San Francisco. The Shokat group discovered a novel, small molecule approach to bind G12C mutant K-Ras and inhibit SOS-catalyzed K-Ras activation1. Building upon those pioneering efforts, Wellspring discovered ARS-853, a cell-active, mutant-specific, covalent inhibitor of KRAS G12C that targets the GDP-bound, inactive state and prevents subsequent activation of KRAS2. Wellspring discovered ARS-1620, the first small molecule inhibitor that induced tumor regression in patient-derived tumor models that served as a valuable pharmacologic tool to interrogate KRAS biology in vivo3. Wellspring, through Araxes Pharma, entered into an exclusive arrangement with Janssen in February 2013 to develop small molecule inhibitors of the KRAS G12C oncoprotein for the treatment of cancer. Scientists at both Wellspring and Janssen have made significant contributions in the discovery and development of potent, selective KRAS G12C inhibitors. -
President, Chief Executive Officer And Co-FounderWellspring Biosciences Jun 2012 - Mar 2019Wellspring and its parent company, Araxes Pharma, are closely held and committed to creating breakthrough medicines for the treatment of cancer and other serious diseases. The companies were founded by Yi Liu, Ph.D., Pingda Ren, Ph.D., Kevan Shokat, Ph.D. and Troy Wilson, Ph.D., J.D., based upon pioneering research into KRAS G12C inhibitors conducted by Dr. Shokat, HHMI Investigator and Professor of Molecular and Cellular Pharmacology, and colleagues at the University of California, San Francisco. The Shokat group discovered a novel, small molecule approach to bind G12C mutant K-Ras and inhibit SOS-catalyzed K-Ras activation1. Building upon those pioneering efforts, Wellspring discovered ARS-853, a cell-active, mutant-specific, covalent inhibitor of KRAS G12C that targets the GDP-bound, inactive state and prevents subsequent activation of KRAS2. Wellspring discovered ARS-1620, the first small molecule inhibitor that induced tumor regression in patient-derived tumor models that served as a valuable pharmacologic tool to interrogate KRAS biology in vivo3. Wellspring, through Araxes Pharma, entered into an exclusive arrangement with Janssen in February 2013 to develop small molecule inhibitors of the KRAS G12C oncoprotein for the treatment of cancer. Scientists at both Wellspring and Janssen have made significant contributions in the discovery and development of potent, selective KRAS G12C inhibitors.
-
Executive Chairman Of The Board Of DirectorsAvidity Biosciences, Inc. Nov 2012 - PresentSan Diego, California, UsAvidity Biosciences is a privately held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease. -
President, Ceo And Co-FounderAvidity Biosciences, Inc. Jan 2013 - Feb 2019San Diego, California, UsAvidity Biosciences is a privately held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.
-
Member Board Of DirectorsPuma Biotechnology Oct 2013 - PresentPuma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2-positive metastatic breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.
-
President, Ceo And Co-FounderIntellikine Aug 2007 - Jan 2012Intellikine was a leading private company focused on the development of innovative, small molecule drugs targeting the PI3K/mTOR pathway for the treatment of cancer and other serious diseases. Founded in September 2007, Intellikine raised $41 million from a group of leading investors, including Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, Abingworth, U.S. Venture Partners, Fintech Global Capital and Biogen Idec. The company was acquired in December 2011 by Takeda Pharmaceuticals for up to $310 million.
-
President And Co-FounderWildcat Discovery Technologies 2006 - 2007San Diego, California, UsWildcat Discovery Technologies accelerates the discovery of new materials for energy applications, with a focus on the development of advanced materials for rechargeable and primary batteries. Wildcat’s business also includes collaborative development projects for materials for other applications, including gas storage, carbon capture, thermoelectrics, and structural materials. Wildcat synthesizes and evaluates thousands of materials every week. To do this, we use proprietary unique-in-the-world high throughput synthesis and testing platforms to rapidly explore thousands of new materials with the goal of improving performance and reducing costs. Our massively parallel combinatorial chemistry approach reduces R&D costs and speeds time to market. The reduction in experimental cost also enables exploration of high risk targets that are often never explored. For example, one battery project involved the exploration of over 1000 unique electrolyte formulations in less than three months. Wildcat employs an experienced team of scientists and engineers, with backgrounds in batteries, materials development, and high throughput automation. Wildcat is pursuing partnership and collaboration opportunities with corporate leaders throughout the battery supply chain, including global material suppliers, cell makers, and OEM’s throughout the automotive, electronics, medical, military, and consumer products industries. -
Chief Business Officer And FounderAmbrx 2003 - 2006San Diego, Ca, UsAmbrx®, Inc. was a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™. Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. The Ambrx advantage allows us to safely and effectively target cytotoxic agents or recruit effector function to tumor cells (oncology) or modulate biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular. -
Vice President, Business Development And General CounselGnf 2000 - 2003San Diego, Ca, Us
Troy Wilson Education Details
-
New York University School Of LawLaw -
University Of California, BerkeleyBiorganic Chemistry
Frequently Asked Questions about Troy Wilson
What company does Troy Wilson work for?
Troy Wilson works for Kura Oncology, Inc.
What is Troy Wilson's role at the current company?
Troy Wilson's current role is Chief Executive Officer.
What schools did Troy Wilson attend?
Troy Wilson attended New York University School Of Law, University Of California, Berkeley.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial